SCHEMBL2231073

SCHEMBL2231073

COc1ccc2cc(-c3ccccc3)c(C(=O)C(=O)Nc3ccc(NCCCNc4cc(C)cc(C)n4)cc3)n2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
HTT P42858 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 5/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 3/20 0.37
THRB P10828 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPK10 P53779 1/20 0.37
CTSK P43235 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PPARG P37231 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NR2E3 Q9Y5X4 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
USP2 O75604 1/20 0.34
IGF1R P08069 1/20 0.34
ATM Q13315 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646815 0.97 LMNA (0.40) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1645787 0.91 LMNA (0.38) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL2231070 0.89 LMNA (0.40) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL2230727 0.88 SMN1; SMN2 (0.42) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1645448 0.87 LMNA (0.39) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1646091 0.86 LMNA (0.38) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1645789 0.86 LMNA (0.36) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1645550 0.86 SMN1; SMN2 (0.41) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1646094 0.86 LMNA (0.41) LMNAHTTSMN1; SMN2MAPTKDM4E
SCHEMBL1645575 0.84 SMN1; SMN2 (0.53) LMNAHTTSMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 LMNA 3870/4885HTT 1809/4885SMN1; SMN2 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.